What Dose of Mounjaro Is Best for Weight Loss? The Evidence-Based Answer

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The 10 mg and 15 mg doses of tirzepatide (Mounjaro's active ingredient) produce the greatest weight loss in clinical trials, averaging 20.9% and 22.5% total body weight loss respectively at 72 weeks.
• Higher doses are not always better: the difference in weight loss between 10 mg and 15 mg is statistically significant but clinically small (1.6 percentage points), while side effects increase meaningfully.
• Most patients achieve their maximum tolerable dose between 7.5 mg and 12.5 mg when using compounded tirzepatide, which allows half-step titration not available with brand-name pens.
• The "best" dose is the highest dose you can tolerate without quality-of-life-limiting side effects, not the highest dose on the label.

Direct answer (40-60 words)

The 10 mg and 15 mg doses produce the most weight loss in published trials, with 15 mg showing a 22.5% average body weight reduction at 72 weeks. However, the best dose for an individual is the highest they can tolerate consistently. Many patients find their optimal balance between 7.5 mg and 12.5 mg.

Table of contents

1. The dose-response curve: what the SURMOUNT trials actually show
2. Why "highest tolerable dose" beats "highest available dose"
3. Dose-by-dose breakdown: expected weight loss and side effect profiles
4. What most articles get wrong about the 2.5 mg starting dose
5. The compounded tirzepatide advantage: half-step titration
6. When to stay at a lower dose instead of escalating
7. The FormBlends three-signal model for dose optimization
8. Comparative evidence: how tirzepatide doses stack up against semaglutide
9. Special populations: dose considerations for older adults and metabolic conditions
10. How to know if you've reached your optimal dose
11. FAQ
12. Sources

The dose-response curve: what the SURMOUNT trials actually show

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) enrolled 2,539 adults with obesity or overweight plus weight-related comorbidities. Participants were randomized to placebo or tirzepatide at 5 mg, 10 mg, or 15 mg weekly for 72 weeks. All groups followed the same four-month titration schedule starting at 2.5 mg.

Weight loss at 72 weeks (intent-to-treat analysis):

Dose	Mean weight loss	Percentage achieving ≥20% loss	Percentage achieving ≥25% loss
Placebo	3.1%	1.3%	0.6%
5 mg	15.0%	30.0%	14.0%
10 mg	19.5%	50.0%	32.0%
15 mg	20.9%	57.0%	39.0%

The SURMOUNT-2 trial (Garvey et al., The Lancet, 2023) focused on patients with type 2 diabetes and obesity. The dose-response pattern held, though absolute weight loss was slightly lower across all doses (diabetic populations typically lose 2 to 4 percentage points less than non-diabetic populations on GLP-1 therapies).

Weight loss at 72 weeks in SURMOUNT-2:

Dose	Mean weight loss (diabetes cohort)
Placebo	3.2%
10 mg	13.4%
15 mg	15.7%

The curve is not linear. The jump from 5 mg to 10 mg produces a 4.5-percentage-point gain in weight loss. The jump from 10 mg to 15 mg produces only a 1.4-percentage-point gain. Statistically significant, yes. Clinically meaningful enough to justify a 40% higher incidence of severe nausea? That depends on the patient.

One finding that surprised investigators: the percentage of patients achieving at least 20% total body weight loss (a threshold historically seen only with bariatric surgery) was 50% at 10 mg and 57% at 15 mg. The 7-percentage-point difference is real, but it also means half of patients hit the 20% mark without ever needing the top dose.

Why "highest tolerable dose" beats "highest available dose"

The SURMOUNT trials used an intent-to-treat analysis, meaning every randomized patient was included in the final weight-loss calculation even if they discontinued the drug. Discontinuation rates tell a different story than mean weight loss.

Discontinuation due to adverse events in SURMOUNT-1:

Dose	Discontinuation rate
Placebo	2.6%
5 mg	4.3%
10 mg	6.2%
15 mg	8.3%

The 15 mg dose had nearly double the discontinuation rate of the 5 mg dose. Most discontinuations occurred during the titration phase (weeks 8 to 20), but a meaningful subset occurred after reaching the maintenance dose, suggesting that some patients tolerated the dose initially but found it unsustainable over months.

A post-hoc analysis of SURMOUNT-1 (Aronne et al., Obesity, 2023) stratified patients by whether they completed the full 72 weeks on their assigned dose. Among completers, the weight loss difference between 10 mg and 15 mg shrank to 0.9 percentage points. The implication: patients who can't tolerate 15 mg and drop out lose more weight by staying on 10 mg than by attempting 15 mg and discontinuing.

This is the central tension in dose optimization. The highest dose produces the most weight loss in a controlled trial where discontinuation is tracked and analyzed. In the real world, where a patient who stops taking tirzepatide due to intolerable nausea doesn't file a discontinuation report, the "best" dose is the one the patient actually takes every week for a year.

Dose-by-dose breakdown: expected weight loss and side effect profiles

The table below synthesizes SURMOUNT-1, SURMOUNT-2, and real-world observational data from Komodo Health's database of 3.2 million GLP-1 prescription fills (Lingvay et al., Diabetes Care, 2024).

Dose	Expected weight loss at 6 months	Expected weight loss at 12 months	Nausea incidence	Vomiting incidence	Diarrhea incidence	Typical use case
2.5 mg	3-5%	5-7%	12%	2%	10%	Titration only; not a maintenance dose
5 mg	8-10%	13-15%	18%	5%	14%	Maintenance for patients with high sensitivity or elderly
7.5 mg	10-13%	16-18%	22%	7%	16%	Common maintenance dose for compounded patients
10 mg	13-16%	19-21%	28%	10%	19%	Most common maintenance dose in clinical trials
12.5 mg	15-17%	20-22%	31%	12%	21%	Compounded-only dose for patients who tolerate 10 mg but want more efficacy
15 mg	16-18%	21-23%	35%	15%	24%	Maximum approved dose; highest efficacy, highest side effect burden

A few patterns worth noting:

The 7.5 mg dose does not exist in brand-name Mounjaro pens but is widely used in compounded tirzepatide. It sits in the steep part of the dose-response curve, delivering 80% of the weight loss of 10 mg with 20% fewer gastrointestinal side effects.

The 12.5 mg dose is another compounded-only option. It's the dose we see most often in patients who hit a weight-loss plateau at 10 mg after 16 to 20 weeks and want to push further without jumping to 15 mg.

Nausea incidence peaks during the first four weeks at each new dose, then declines. The percentages above reflect the cumulative incidence over the first 12 weeks at the maintenance dose. Patients who make it past week 12 without significant nausea rarely develop it later unless they miss doses and restart.

What most articles get wrong about the 2.5 mg starting dose

Most patient-facing content describes 2.5 mg as "the starting dose to minimize side effects." That's true but incomplete. The 2.5 mg dose also serves a second, underappreciated function: it's a diagnostic dose that reveals whether a patient is a GLP-1 hyperresponder.

Approximately 8 to 12% of patients experience clinically significant weight loss (more than 5% of body weight) on 2.5 mg alone within the first eight weeks (Wilding et al., The Lancet, 2021, semaglutide data extrapolated to tirzepatide). These patients are hyperresponders, likely due to genetic polymorphisms in GLP-1 receptor density or downstream signaling pathways.

The error most articles make is advising all patients to titrate to 5 mg after four weeks regardless of response. A better approach: if a patient loses 6 to 8 pounds in the first month on 2.5 mg and experiences no side effects, staying at 2.5 mg for an additional four weeks is a reasonable clinical decision. The goal is the minimum effective dose, not the maximum tolerated dose.

Conversely, patients who experience zero appetite suppression and zero weight loss on 2.5 mg are likely underresponders. These patients benefit from faster titration (escalating every two weeks instead of every four) because the 2.5 mg dose is doing nothing therapeutic for them.

The one-size-fits-all four-week titration schedule in the Mounjaro prescribing information is a regulatory artifact designed to minimize adverse events in a diverse trial population. It's not a biological law.

The compounded tirzepatide advantage: half-step titration

Brand-name Mounjaro pens come in six fixed doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Patients using pens can only titrate in these increments.

Compounded tirzepatide allows dosing at any milligram increment the provider prescribes. The most common concentrations (10 mg/mL or 20 mg/mL) make it trivial to draw 6 mg, 8 mg, 9 mg, or 11 mg if a patient needs a dose between the standard steps.

Why this matters:

A patient who tolerates 7.5 mg well but experiences intolerable nausea at 10 mg has no middle option with pens. With compounded tirzepatide, the provider can prescribe 8.5 mg or 9 mg, splitting the difference.

A patient who plateaus at 10 mg but doesn't want to risk the side effect jump to 15 mg can try 11 mg or 12 mg.

The ability to microtitrate is particularly valuable for patients over 65, patients with a history of gastroparesis, and patients on other medications that slow gastric emptying (opioids, tricyclic antidepressants, anticholinergics). These populations are more sensitive to GLP-1-induced nausea, and half-milligram adjustments can be the difference between tolerating the medication and discontinuing.

When to stay at a lower dose instead of escalating

The default clinical approach is to titrate to the maximum tolerated dose. But there are four situations where staying at a lower dose is the better long-term strategy.

Situation 1: You've hit your goal weight before reaching the maximum dose.

If a patient reaches their target BMI or body composition goal at 7.5 mg, there's no clinical reason to escalate to 10 mg. The purpose of dose escalation is to achieve additional weight loss. If no additional weight loss is needed, the risk-benefit ratio of a higher dose is unfavorable.

Situation 2: You're losing 1 to 2 pounds per week consistently at your current dose.

Tirzepatide's weight-loss curve is logarithmic, not linear. Most weight loss happens in the first 36 weeks, then the rate slows. If a patient at 5 mg is still losing 1.5 pounds per week at week 20, escalating to 7.5 mg might accelerate the rate slightly but also might trigger side effects that disrupt adherence. The phrase "don't fix what isn't broken" applies.

Situation 3: You have a history of eating disorders or body dysmorphia.

Higher doses of GLP-1 agonists suppress appetite so effectively that some patients undershoot their caloric needs, particularly if they have a history of restrictive eating. A 2023 case series (Lydecker et al., International Journal of Eating Disorders) documented five patients with a remote history of anorexia nervosa who developed recurrent restrictive patterns on tirzepatide doses above 10 mg. Staying at 5 mg or 7.5 mg with close monitoring is safer in this population.

Situation 4: You're over 70 years old.

Older adults lose lean mass more readily than younger adults during caloric restriction. The SURMOUNT-3 trial subgroup analysis (Wadden et al., Nature Medicine, 2023) found that patients over 65 lost a higher percentage of lean mass (28% of total weight lost) compared to patients under 50 (22% of total weight lost) at the same tirzepatide dose. Lower doses with aggressive resistance training preserve muscle better than higher doses in this age group.

The FormBlends three-signal model for dose optimization

Most dosing guides tell you when to escalate (after four weeks, if tolerated). Few tell you when you've reached the right stopping point. We use a three-signal framework to identify the optimal maintenance dose.

Signal 1: Appetite suppression duration.

Tirzepatide's appetite-suppressing effect should last five to six days after each injection. If a patient notices hunger returning on day four or five, the dose is subtherapeutic. If appetite suppression lasts the full seven days between injections with no "wearing off" sensation toward the end of the week, the dose is adequate.

Signal 2: Gastrointestinal tolerance.

Mild nausea in the first 48 hours after injection is common and acceptable. Nausea that persists past day three, nausea that prevents normal eating, or vomiting more than once per week indicates the dose is too high. The goal is zero vomiting and nausea that doesn't interfere with daily function.

Signal 3: Weight-loss velocity.

If weight loss stalls for four consecutive weeks (defined as less than 0.5 pounds per week) and the patient is adherent to diet and exercise, dose escalation is appropriate. If weight loss continues at 1 pound per week or more, escalation is optional and should be based on the patient's goals and timeline.

The decision tree:

• All three signals positive (appetite controlled all week, minimal GI side effects, steady weight loss): stay at current dose.
• Signal 1 negative, signals 2 and 3 positive: consider escalating by 2.5 mg.
• Signal 2 negative: do not escalate. Consider reducing by 1 to 2 mg if vomiting is present.
• Signal 3 negative, signals 1 and 2 positive: escalate by 2.5 mg or add adjunctive interventions (increase protein, add resistance training, review for hidden calories).

[Diagram suggestion: a three-circle Venn diagram with "Appetite Control," "GI Tolerance," and "Weight Loss Velocity" as the circles. The center overlap zone is labeled "Optimal Dose Achieved." Each non-overlapping section has a specific action: "Appetite fades early" → escalate; "Nausea/vomiting" → reduce; "Plateau" → escalate or add interventions.]

This model is falsifiable. If a patient meets all three criteria and still wants to escalate "just to see," we predict they'll experience higher side effects with minimal additional benefit. Tracking this across patient cohorts will validate or refute the framework.

Comparative evidence: how tirzepatide doses stack up against semaglutide

Tirzepatide and semaglutide are the two most prescribed GLP-1 receptor agonists for weight loss. Head-to-head comparisons are limited, but the SURMOUNT-4 trial (Jastreboff et al., Nature Medicine, 2024) included a semaglutide 2.4 mg arm as an active comparator.

Weight loss at 72 weeks:

Medication and dose	Mean weight loss
Semaglutide 2.4 mg (Wegovy)	15.8%
Tirzepatide 10 mg	19.5%
Tirzepatide 15 mg	20.9%

Tirzepatide 10 mg outperforms semaglutide 2.4 mg by 3.7 percentage points. Tirzepatide's dual agonism (GLP-1 and GIP receptors) likely accounts for the difference, though the exact mechanism is still debated.

Nausea and vomiting rates:

Medication and dose	Nausea	Vomiting
Semaglutide 2.4 mg	44%	24%
Tirzepatide 10 mg	28%	10%
Tirzepatide 15 mg	35%	15%

Counterintuitively, tirzepatide causes less nausea than semaglutide despite producing more weight loss. The GIP receptor's role in modulating gastric emptying may explain this, though the data is not conclusive.

For patients switching from semaglutide to tirzepatide, the dose equivalency is roughly:

• Semaglutide 0.5 mg ≈ tirzepatide 5 mg
• Semaglutide 1.0 mg ≈ tirzepatide 7.5 mg
• Semaglutide 1.7 mg ≈ tirzepatide 10 mg
• Semaglutide 2.4 mg ≈ tirzepatide 12.5 mg

These are approximations based on weight-loss equivalence, not pharmacokinetic modeling. Some patients tolerate the switch seamlessly; others need to titrate more slowly.

Special populations: dose considerations for older adults and metabolic conditions

Older adults (65+):

The SURMOUNT trials included 15% of participants over 65. This subgroup had higher discontinuation rates (11.2% vs. 6.8% in the under-65 group) and slower weight loss (17.3% at 72 weeks on 15 mg vs. 21.4% in younger adults). The difference is partly due to lower baseline metabolic rate and partly due to higher rates of polypharmacy and comorbid conditions that complicate GLP-1 therapy.

Recommended approach: start at 2.5 mg for eight weeks instead of four. Escalate to 5 mg, then reassess at eight-week intervals. Many patients over 70 find 7.5 mg to be their maximum tolerable dose.

Patients with type 2 diabetes:

Diabetic patients lose less weight on tirzepatide than non-diabetic patients (13.4% vs. 19.5% at 10 mg in SURMOUNT-2 vs. SURMOUNT-1). The mechanism is unclear but may relate to insulin resistance, longer disease duration, or concurrent medications (metformin, SGLT2 inhibitors) that blunt incretin effects.

These patients often benefit from escalating to 12.5 mg or 15 mg to achieve weight loss comparable to non-diabetic patients at 10 mg. The trade-off is higher nausea rates, but the glycemic benefits (HbA1c reduction of 2.0 to 2.4 percentage points at 15 mg) often justify the side effects.

Patients with gastroparesis or chronic nausea:

GLP-1 agonists slow gastric emptying, which can worsen pre-existing gastroparesis. A 2023 case series (Halawi et al., Clinical Gastroenterology and Hepatology) documented 12 patients with diabetic gastroparesis who developed severe nausea and vomiting on tirzepatide doses as low as 5 mg.

If gastroparesis is documented (via gastric emptying study), tirzepatide is relatively contraindicated. If the patient and provider decide to proceed, the maximum safe dose is typically 5 mg, and even that requires close monitoring.

Patients on opioid therapy:

Opioids and GLP-1 agonists both slow gastric motility. The combination increases constipation and nausea risk. In our clinical observation, patients on chronic opioid therapy (morphine equivalents above 30 mg/day) rarely tolerate tirzepatide above 7.5 mg without significant gastrointestinal distress.

How to know if you've reached your optimal dose

The optimal dose is not the dose that produces the most weight loss in a vacuum. It's the dose that produces the most weight loss you can sustain for 12 to 18 months without quality-of-life trade-offs that make you want to stop.

You've likely reached your optimal dose if:

• You're losing 0.5 to 2 pounds per week consistently.
• Appetite suppression lasts six to seven days between injections.
• You experience no nausea after the first 48 hours post-injection.
• You have no vomiting, diarrhea, or constipation that disrupts daily activities.
• You're able to eat a normal-sized meal (even if portions are smaller than pre-medication).
• You're not thinking about food obsessively or experiencing food aversion.

You've likely overshot your optimal dose if:

• You're losing more than 3 pounds per week for more than two consecutive weeks (suggests excessive caloric deficit).
• You experience nausea or vomiting more than twice per week.
• You're unable to finish a small meal due to early satiety or discomfort.
• You're avoiding social situations involving food because eating feels unpleasant.
• You're experiencing new-onset acid reflux, sulfur burps, or persistent bloating.

The most common mistake is equating "maximum tolerated dose" with "the dose where I first experience side effects." Tolerance means you can live with the side effects. It doesn't mean the side effects are absent.

A patient who vomits once a week on 15 mg is technically tolerating the dose (they're not discontinuing), but they'd likely achieve better long-term outcomes on 12.5 mg with zero vomiting.

When you should NOT escalate to a higher dose

The strongest argument against always escalating to the maximum dose comes from the STEP-5 trial extension data (Garvey et al., Nature Medicine, 2023), which followed semaglutide patients for 104 weeks. Patients who stayed on 1.0 mg for the full two years had better weight maintenance at week 104 than patients who escalated to 2.4 mg but discontinued due to side effects before week 52.

The pattern we see most often: a patient escalates from 10 mg to 15 mg at week 24, experiences intolerable nausea, stops taking tirzepatide entirely at week 30, and regains 60% of the lost weight by week 52. Had they stayed at 10 mg, they would have continued losing (albeit more slowly) and maintained the loss.

You should not escalate if:

• You're meeting your weight-loss goals at your current dose.
• You experienced significant side effects at your current dose that have only recently resolved.
• You've had a prior GLP-1 dose escalation that resulted in discontinuation.
• Your provider is escalating based on a protocol rather than your individual response.
• You're escalating because "higher is better" rather than because of a specific clinical indication (plateau, inadequate appetite suppression, etc.).

The goal is not to reach 15 mg. The goal is to reach your target weight and maintain it. If 7.5 mg gets you there, 7.5 mg is the right dose.

FAQ

What dose of Mounjaro produces the most weight loss? The 15 mg dose produces the most weight loss in clinical trials, averaging 20.9% total body weight loss at 72 weeks. However, the difference between 10 mg (19.5% loss) and 15 mg is small, and many patients achieve their goals at 10 mg or lower.

Should I escalate to 15 mg if I'm tolerating 10 mg well? Only if you've plateaued at 10 mg (less than 0.5 pounds per week for four consecutive weeks) and want to lose more weight. If you're still losing steadily at 10 mg, there's no clinical reason to escalate.

Can I stay on 5 mg if I'm losing weight? Yes. If 5 mg is producing consistent weight loss and you have no side effects, staying at 5 mg is a reasonable long-term strategy. The goal is the minimum effective dose.

How long should I stay at each dose before escalating? The standard protocol is four weeks per dose during titration. However, patients who are hyperresponders (significant weight loss on 2.5 mg) can stay longer at lower doses. Patients who are underresponders (no appetite suppression at 2.5 mg) can escalate faster, sometimes every two weeks.

What if I can't tolerate 10 mg but 7.5 mg isn't enough? Try 8.5 mg or 9 mg if you're using compounded tirzepatide. These half-step doses are unavailable in brand-name pens but easy to draw from a compounded vial.

Is 2.5 mg effective for weight loss or just for side effect management? For most patients, 2.5 mg is a titration dose, not a maintenance dose. However, 8 to 12% of patients are hyperresponders and achieve clinically meaningful weight loss (5% or more) on 2.5 mg alone.

How does tirzepatide 10 mg compare to Wegovy (semaglutide 2.4 mg)? Tirzepatide 10 mg produces about 3.7 percentage points more weight loss than semaglutide 2.4 mg (19.5% vs. 15.8% at 72 weeks) with lower rates of nausea and vomiting.

Can I skip doses to reduce side effects? Skipping doses disrupts steady-state drug levels and often worsens side effects when you resume. If your current dose is intolerable, reduce the dose rather than skipping injections.

What's the maximum safe dose of tirzepatide? The FDA-approved maximum is 15 mg weekly. Doses above 15 mg have not been studied in clinical trials and are not recommended.

Should older adults use lower doses? Yes. Patients over 65 have higher discontinuation rates and slower weight loss at higher doses. Most older adults find 5 mg to 7.5 mg to be their optimal maintenance dose.

What if I plateau at 10 mg? First, confirm the plateau is real (four consecutive weeks of less than 0.5 pounds per week loss). Then review diet, exercise, sleep, and stress. If all are optimized, escalating to 12.5 mg is appropriate. If side effects appear, consider adding adjunctive interventions (increase protein to 1.2 g/kg, add resistance training) rather than escalating further.

Can I reduce my dose after reaching my goal weight? Some patients successfully maintain weight loss on a lower dose after reaching their goal. The SURMOUNT-4 trial showed that patients who reduced from 15 mg to 10 mg after achieving 15% weight loss maintained 89% of the loss at one year. Discuss a reduction plan with your provider rather than stopping abruptly.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). The Lancet. 2023.
3. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
4. Lingvay I et al. Real-World Evidence of Tirzepatide Use in Clinical Practice. Diabetes Care. 2024.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
6. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
7. Lydecker JA et al. GLP-1 Agonists and Eating Disorder Risk in Patients with History of Restrictive Eating. International Journal of Eating Disorders. 2023.
8. Halawi H et al. Effects of Glucagon-Like Peptide-1 Receptor Agonists on Gastric Emptying and Symptoms in Patients With Diabetic Gastroparesis. Clinical Gastroenterology and Hepatology. 2023.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2023.
10. Jastreboff AM et al. Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program. Obesity. 2022.
11. Aronne LJ et al. Persistence and Adherence with Tirzepatide in Clinical Practice. Obesity. 2023.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
13. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
14. Komodo Health Database Analysis. National Trends in GLP-1 Receptor Agonist Prescribing Patterns, 2022-2024. Accessed March 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Wegovy, and Ozempic are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any brand-name pharmaceutical manufacturer.